Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Walmart Stores Inc (WMT) Price & Performance

Abeona Therapeutics IncTrade
Walmart Stores IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Walmart Stores Inc — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while Walmart Stores Inc trades at $114.63 (market cap $901.33B). The key difference: Walmart Stores Inc is far larger — about 2140× Abeona Therapeutics Inc's market cap, and Walmart Stores Inc pays a 0.87% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOWMT
Market Cap
$421.19M$901.33B
Sector
HealthConsumer Staples
52-Week High
$7.45$134.20
52-Week Low
$4.17$96.05
Enterprise Value
$276.10M$964.78B
Volume
5,675,288
Dividend Yield
0.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Walmart Stores Inc

Walmart (WMT) trades at $112.66, up 0.72% with strong fundamental performance including three consecutive quarterly EPS beats and robust revenue growth to $681B in 2025. The stock shows neutral technical signals with RSI at 62.52, while analyst consensus remains strongly bullish with a $142 price target. Recent developments include AI tool innovations and expanded delivery services positioning the company for continued market leadership.

Walmart presents a compelling investment case with solid fundamentals and analyst support, though valuation multiples appear elevated. Key opportunities include sustained revenue growth and operational efficiency gains, while risks involve competitive pressures from Amazon and potential margin compression. The stock offers 26% upside to consensus targets but requires monitoring of execution against high expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Walmart Stores Inc

Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.

Read more on WMT